41 related articles for article (PubMed ID: 11845989)
1. Androgen and its receptor promote Bax-mediated apoptosis.
Lin Y; Kokontis J; Tang F; Godfrey B; Liao S; Lin A; Chen Y; Xiang J
Mol Cell Biol; 2006 Mar; 26(5):1908-16. PubMed ID: 16479009
[TBL] [Abstract][Full Text] [Related]
2. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
[TBL] [Abstract][Full Text] [Related]
3. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Schayowitz A; Sabnis G; Goloubeva O; Njar VC; Brodie AM
Br J Cancer; 2010 Sep; 103(7):1001-7. PubMed ID: 20842117
[TBL] [Abstract][Full Text] [Related]
4. Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Mad'arová J; Lukesová M; Hlobilková A; Strnad M; Vojtesek B; Lenobel R; Hajdúch M; Murray PG; Perera S; Kolár Z
Mol Pathol; 2002 Aug; 55(4):227-34. PubMed ID: 12147712
[TBL] [Abstract][Full Text] [Related]
5. Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?
Krycer JR; Brown AJ
PLoS One; 2013; 8(1):e54007. PubMed ID: 23320115
[TBL] [Abstract][Full Text] [Related]
6. Targeting androgen receptor (AR) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR-expressing prostate cancer cell lines.
Jamshidi M; Keshavarzi F; Amini S; Laher I; Gheysarzadeh A; Davari K
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1922. PubMed ID: 37903548
[TBL] [Abstract][Full Text] [Related]
7. TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.
Liang C; Wang S; Qin C; Bao M; Cheng G; Liu B; Shao P; Lv Q; Song N; Hua L; Gu M; Li J; Wang Z
Cell Death Dis; 2018 Feb; 9(2):155. PubMed ID: 29449534
[TBL] [Abstract][Full Text] [Related]
8. In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2011 Dec; 3(6):243-50. PubMed ID: 22164193
[TBL] [Abstract][Full Text] [Related]
9. Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.
Stubbs AP; Abel PD; Golding M; Bhangal G; Wang Q; Waxman J; Stamp GW; Lalani EN
Am J Pathol; 1999 May; 154(5):1335-43. PubMed ID: 10329586
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor signaling regulates T-type Ca
Hall M; Todd B; Allen ED; Nguyen N; Kwon YJ; Nguyen V; Hearne JL; Martin-Caraballo M
Am J Cancer Res; 2018; 8(4):732-747. PubMed ID: 29736318
[TBL] [Abstract][Full Text] [Related]
11. Nuclear receptors in early hormone refractory prostate cancer and their relationship to apoptosis-related proteins.
Kolár Z; Murray PG; Madarova J; Lukesova M; Hlobilkova A; Riháková P; Flavell P; Strnad M; Student V; Vojtesek B
Neoplasma; 2002; 49(3):172-7. PubMed ID: 12098003
[TBL] [Abstract][Full Text] [Related]
12. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
Griffiths K; Morton MS; Nicholson RI
Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
[TBL] [Abstract][Full Text] [Related]
13. Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer.
Baltogiannis D; Charalabopoulos K; Giannakopoulos X; Karakosta A; Sofikitis N
Exp Oncol; 2005 Jun; 27(2):91-3. PubMed ID: 15995623
[TBL] [Abstract][Full Text] [Related]
14. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
15. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
